skip to main content

Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

EasyBreast CancerBreast CancerSCE Medical Oncology

A 62-year-old woman with de novo metastatic ER+/HER2- breast cancer has bone-only disease. ECOG PS 0. Postmenopausal. What is the standard first-line therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Aromatase inhibitor + CDK4/6 inhibitor

For postmenopausal de novo ER+/HER2- MBC without visceral crisis, AI + CDK4/6 inhibitor is standard first-line (NICE TA495/596/810). PFS ~25-28 months. Chemo is not first-line here.

Reference: NICE TA495 Palbociclib; ESMO 2024 Metastatic Breast Cancer Guidelines